Prevention of type 2 diabetes: are we ready?
Type 2 diabetes is the most common metabolic disease. The cost of diabetes to the individual and to society, and the pandemic prevalence makes disease prevention of extreme importance. Persons with impaired glucose tolerance, modest elevations in blood glucose that remain below levels diagnostic for diabetes, are at increased risk of progression to overt diabetes. New studies evaluate the role of lifestyle interventions including diet and exercise, and the potential role of multiple classes of pharmaceutical agents including the insulin sensitizers, biguanides and thiazolidendiones, and carbohydrase and lipase inhibitors in disease prevention of such high-risk individuals. Many of these strategies appear to be effective to delay, and perhaps prevent, the development of type 2 diabetes and thus should be considered for broader clinical application. Awareness of the extent of the problem and the potential benefits of prevention needs to be raised in both physicians and in the at high risk population.
Joslin Diabetes Center, Boston, MA 02215, USA. Allison.Goldfine@Joslin.Harvard.Edu
C
C
Bouche
A B
AB
Goldfine
D002839:Chromans / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000517:prevention & control*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007783:Lactones / Q000627:therapeutic use; D008019:Life Style; D008049:Lipase / Q000037:antagonists & inhibitors; D008687:Metformin / Q000627:therapeutic use; D000077403:Orlistat; D013844:Thiazoles / Q000627:therapeutic use; D045162:Thiazolidinediones; D000077288:Troglitazone
D002839:Chromans; D007004:Hypoglycemic Agents; D007783:Lactones; D013844:Thiazoles; D045162:Thiazolidinediones; D008687:Metformin; D000077403:Orlistat; D008049:Lipase; D000077288:Troglitazone